SEC Puts US-Listed Chinese Biopharma Firms On Notice To Comply With 2020 Law
Non-Compliance Means Nasdaq De-Listing In 2024
Chinese companies publicly traded in the US – including BeiGene, HutchMed and Zai Lab – have three years to switch to accounting firms that can be investigated by the US government, or two years if a pending amendment is adopted.
